<SEC-DOCUMENT>0001213900-24-024197.txt : 20240320
<SEC-HEADER>0001213900-24-024197.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320090622
ACCESSION NUMBER:		0001213900-24-024197
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240320
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		24766465

	BUSINESS ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0202110-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of March 2024 (Report No. 4)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-39957</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NLS
PHARMACEUTICS LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Circle 6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>8058
Zurich, Switzerland</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 19, 2024, NLS Pharmaceutics
Ltd., or the Registrant, entered into an exclusive license agreement, or the License Agreement, with Aexon Labs Inc. a Delaware corporation,
or Aexon. Pursuant to the License Agreement, Aexon granted the Registrant an exclusive, royalty-bearing license, or the License, with
the right to grant sublicenses in multiple tiers according to the terms of the License Agreement. Subject to earlier termination of the
License Agreement in accordance with its terms, the term of the License Agreement is from the effective date of the License Agreement
to the latest of (i) the Registrant&rsquo;s termination of the commercialization of one or more pharmaceutical or therapeutic products,
or any combination thereof, in the use of such compounds for narcolepsy and other neuro degenerative disorders in the last region and
country in which commercialization had actually begun, and (ii) the expiration of the last-to-expire Valid Claim (as defined in the License
Agreement) of a patent identified in the License Agreement and patents owned by Aexon as of the date of the License Agreement, that covers
such pharmaceutical or therapeutic product for the use of such compounds for narcolepsy and other neuro degenerative disorders in the
respective country or region in which it was used. Pursuant to the terms of the License Agreement, the Registrant agreed to pay Aexon
a royalty on a country-by-country basis of 5% to 30% depending on (i) earnings by the Registrant in a specified region or country for
licensed products covered by patents, (ii) whether the applicable patent has not been granted to the applicable product at the time of
commercialization of such product and (iii) whether the Registrant challenges the validity of a patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Registrant must exercise
its exclusive option for the License no later than March 31, 2024, and make an upfront payment of $170,000, otherwise the License Agreement
shall become null and void as of April 1, 2024. The Registrant must also make payments to Aexon upon the occurrence of certain milestones.
Such payments upon the occurrence of milestones contemplated in the License Agreement range from $100,000 to $300,000. Further, pursuant
to the License Agreement, the Registrant has agreed to pay Aexon a percentage of license fees, milestones and royalties received from
sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">A copy of the Registrant&rsquo;s press release announcing entry into the
License Agreement, titled: &ldquo;NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist
Platform Developed by Aexon Labs, Inc,&rdquo; is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report is incorporated by reference into the Registrant&rsquo;s Registration Statements on Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390022005236/ea154797-f3_nlspharma.htm">333-262489</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390022077965/ea169650-f3_nlspharm.htm">333-268690</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390023002775/ea171509-f3_nlspharm.htm">333-269220</A>), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Document</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020211001ex99-1_nlspharma.htm">Press release titled: &ldquo;NLS Pharmaceutics Secures Exclusive Global License for Next-Generation <FONT STYLE="text-decoration: none">Non-Sulfonamide Dual Orexin Agonist Platform&rdquo;</FONT></A></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 20, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020211001ex99-1_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS SECURES EXCLUSIVE GLOBAL LICENSE FOR NEXT-GENERATION NON-SULFONAMIDE DUAL OREXIN AGONIST PLATFORM"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS
Pharmaceutics Secures Exclusive Global License for Next-Generation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Sulfonamide
Dual Orexin Agonist Platform </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide
                                            orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological
                                            therapies.</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Medications
                                            activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders
                                            including narcolepsy and other hypersomnolence disorders</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Additional
                                            targets covered by the exclusive License Agreement include cathepsins, sigma receptors and
                                            catecholaminergic inhibition, addressing neuroprotection, neuroinflammation and neurotransmission.</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>First
                                            patent application was filed at the end of 2022 for orexin receptors agonists for treating
                                            or preventing neurological diseases and psychiatric disorders including narcolepsy.</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
                                            this groundbreaking License Agreement, NLS continues to strengthen its neuroscience pipeline
                                            in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence
                                            and neurodegenerative disorders franchise.</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NLS
                                            to start immediately focusing on these disease modifying compounds which have the potential
                                            to be first as well as best in class.</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Z&uuml;rich,
Switzerland, March 20, 2024</B> &ndash; <FONT STYLE="background-color: white">NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (&ldquo;NLS&rdquo;),
a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced
today a groundbreaking exclusive worldwide license agreement (the &ldquo;License Agreement&rdquo;) with Aexon Labs, Inc., a U.S.-based
biotech firm (&ldquo;Aexon&rdquo;). This license grants NLS the opportunity to acquire global development and commercialization rights
to Aexon&rsquo;s Dual Orexin Receptor Agonists platform. These novel compounds are potent oral agents targeting both orexin-1 and orexin-2
receptors as agonists, with potential applications in narcolepsy, idiopathic hypersomnia, and &alpha;-Synucleinopathies, including Parkinson's
disease, dementia with Lewy bodies, and multiple system atrophy, all of which involve cathepsins.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
License Agreement highlights the transformative potential of these revolutionary chemical compounds compared to first generation sulfa
derivatives, selective OX2R agonists,&rdquo; said Eric Konofal, MD, PhD, who works under a part-time consulting agreement for NLS as
its Chief Scientific Officer, and who is also President of Aexon. He continued, &ldquo;These compounds have focused solely on the role
of orexin-2 receptors (OX2R) in treating the symptomatology of narcolepsy. Emerging scientific insights suggest a broader range of complex
mechanisms at play in the pathophysiology of tetrad narcolepsy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
exclusive, worldwide License Agreement marks a significant milestone in the field of oral therapeutics, highlighting the introduction
of two potentially potent candidates, innovative dual orexin receptor agonists. Anticipated to address critical healthcare requirements,
one compound in particular, has shown encouraging outcomes in preliminary <I>in vitro</I> experiments. Its dual mechanism of action involves
acting as agonist for OX1R and OX2R, while concurrently serving as an inhibitor for cathepsin H (CTSH), showcasing its potential to meet
significant medical needs effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orexin
receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are
involved in pathological processes of neurological diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer&rsquo;s
disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Konofal continued, &ldquo;<FONT STYLE="font-weight: normal">By simultaneously targeting the potential benefits of a compound acting as
both a dual agonist of orexin receptors and an inhibitor of CTSH for the treatment of narcolepsy, we combine the agonist effect on orexin-1
and orexin-2 receptors, which have been shown to improve wakefulness and reduce cataplexy, with the prospective benefits of CTSH inhibition.
Such inhibition is theorized to be able to influence immune responses via HLA-DQB1 and the processing of proteins related to the pathogenesis
of narcolepsy. This double dual-action strategy could offer a comprehensive treatment modality for narcolepsy, addressing both symptom
management and the underlying causes of the disease.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to obtain sufficient funds, Aexon plans to conduct Proof-of-Concept studies in animals and phase 1 First-in-Human clinical development
starting in early 2025. <FONT STYLE="background-color: white">Preliminary findings will be unveiled at the 2024 ASCP Annual Meeting (Miami,
Florida, May 28 - 31).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Zwyer said, &ldquo;I believe acquiring rights to this innovative platform, which includes more than 300 compounds, represents a bridge
from current to future treatments for sleep and neurodegenerative disorders. The addition of these new compounds to our existing pipeline&mdash;Mazindol
ER for narcolepsy, NLS-4 for idiopathic hypersomnia, long-COVID, and chronic fatigue syndrome, and NLS-11 for Kleine-Levin Syndrome and
neurodegenerative diseases&mdash;will significantly enhance and bolster our central disorders of hypersomnolence franchise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NLS
continues ongoing discussions around further development of Mazindol and remains committed to a wide range of options with a focus on
maximizing shareholder value, including strategic partnerships and other future strategic actions. Several partnership opportunities
are currently under way, though have been delayed due to various market factors, but are in advanced stages of negotiations. As always,
we continue to approach the sleep medicine market from a holistic perspective.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Narcolepsy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Narcolepsy
is a life-long sleep disorder caused by the autoimmune-mediated loss of 70,000&ndash;90,000 orexin-producing neurons in the hypothalamus,
characterized by excessive daytime sleepiness, cataplexy and rapid eye movement sleep abnormalities, and is tightly associated with human
leukocyte antigen&nbsp;HLA-DQB1*06:02.&nbsp; Other predisposing factors for narcolepsy are associations with a polymorphism in the&nbsp;T-cell
receptor alpha&nbsp;and&nbsp;beta&nbsp;genes, whose products recognize antigens presented by human leukocyte antigens (HLA) molecules,
and&nbsp;CTSH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NLS Pharmaceutics Ltd. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NLS
is a global development-stage biopharmaceutical company,&nbsp;working with a network of world-class partners and internationally recognized
scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system
disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is&nbsp;led by an experienced management
team with a track record of developing and commercializing product candidates.&nbsp; For more information, please visit&nbsp;www.nlspharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Aexon Labs, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aexon
is conducting leading edge research on new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown
of neurons over time. Alzheimer&rsquo;s, Parkinson&rsquo;s, Huntington&rsquo;s, Narcolepsy and Amyotrophic Lateral Sclerosis are just
a few examples of brain disorders that have no cure. Current treatments do not address the root cause of each disorder and often lack
therapeutical effectiveness and safety for these neurological disorders. For more information, please visit&nbsp;www.aexonlabs.com. Eric
Konofal, MD, PhD, who works under a part-time consulting agreement for NLS as its Chief Scientific Officer, is the president and founder
of Aexon Labs, and owns 59% of Aexon Labs. Alexander Zwyer, Chief Executive Officer of NLS, owns 35% of Aexon Labs. Mr. Zwyer holds no
board or executive position at Aexon Labs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is
using forward-looking statements when it discusses the potential benefits of NLS&rsquo; and Aexon&rsquo;s products, <FONT STYLE="background-color: white">including
Aexon&rsquo;s Dual Orexin Receptor Agonists platform</FONT>, that Aexon&rsquo;s platform&rsquo;s <FONT STYLE="font-weight: normal">double
dual-action strategy could offer a comprehensive treatment modality for narcolepsy, addressing both symptom management and the underlying
causes of the disease, that A</FONT>exon plans to conduct Proof-of-Concept studies in animals and phase 1 First-in-Human clinical development
starting in early 2025 and the expected unveiling of those results, NLS&rsquo; and Aexon&rsquo;s development plans and timing of studies,
the timing and expected outcomes of the License Agreement, and NLS&rsquo; plans to maximize value, including potential strategic partnerships
and other strategic actions. These forward-looking statements and their implications are based on the current expectations of the management
of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles
in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology
may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain
or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop
with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to
equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials;
NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to
timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting
from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting NLS is contained under the heading &quot;Risk Factors&quot; in NLS' annual report
on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (&quot;SEC&quot;), which is available
on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
additional information: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marianne
Lambertson (investors &amp; media)<BR>
NLS Pharmaceutics Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
239.682.8500<BR>
ml@nls-pharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.nlspharmaceutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 5D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MJE?:M8Z:\2W=PL32_=!!.??Z<B@4I**NW8NT4=1D44#"BBL^+7--GU633([I
M&O(QEHQ[=1GUHL)M+<T****!A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
